Study of VG161 for advanced bone and soft tissue sarcoma
Part of Cancer clinical trials.
This trial tests a new virus-based therapy (VG161) injected directly into tumors for people with advanced bone and soft tissue sarcoma that hasn't responded to other treatments. The goal is to see if the virus can shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced bone or soft tissue sarcoma that can't be removed by surgery and has not responded to at least one standard treatment (for Ewing sarcoma, you may not have had any standard treatment yet).
- You have a tumor that is at least 1.5 cm in size that can be injected with the study drug, preferably on the skin surface or visible on ultrasound.
- You have tested positive for HSV-1 antibodies (a virus that causes cold sores).
- You are in generally good health, with adequate organ function (kidney, liver, blood cells, and clotting).
- You have not had other cancer treatments or major surgery in the past 4 weeks, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.